 |
CavoGene LifeSciences
Last updated: May 07, 2024
Scott Fisher, CEO
Country: USA | Funding: $4M (+)
Website: http://www.cavogene.com
CavoGene LifeSciences develops a novel gene therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS), colloquially known as Lou Gherig's disease, and other forms of neurodegeneration.
Website: http://www.cavogene.com
CavoGene LifeSciences develops a novel gene therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS), colloquially known as Lou Gherig's disease, and other forms of neurodegeneration.